Introduction
So-called 'cancer stem cells' (CSCs) represent a population of cancer cells specifically responsible for cancer unlimited growth, for the generation of diverse, more or less differentiated, other cancer cells populations and for resistance to chemotherapy (Dalerba et al., 2007) . Independently of the possible origin of CSC in somatic stem cells (Alison et al., 2010) , the use of this denomination implies some explicit but also implicit assumptions, varying from one author to another, that we and others have previously analyzed (Shackleton et al., 2009; Dirks, 2010; Maenhaut et al., 2010; Roesch et al., 2010; Shackleton, 2010) . To avoid misconceptions, we and others have proposed to call such cells 'tumor-propagating cells' (TPCs) in agreement with their operational demonstration by xenografts (Kelly et al., 2007; Hong et al., 2008; Maenhaut et al., 2010) . In this review, we shall use the term CSC-TPC to designate these cells except when citing authors who emphasized the 'CSC' denomination when describing their findings. We do not use the term CSC-tumorinitiating cell, as this term (Mani et al., 2008) could lead to a confusion with the cells in which the cancer was initiated in vivo. The highly productive concept of CSC-TPC (Lapidot et al., 1994; Clarke and Fuller, 2006; Kelly et al., 2007; Hong et al., 2008; Alison et al., 2011) has represented a major advance in cancer research.
CSC-TPC are often assumed to generate the bulk of cancer cells, the derived cells, by a deterministic and irreversible process. We and others (Shackleton et al., 2009; Dirks, 2010; Maenhaut et al., 2010; Roesch et al., 2010) have argumented that this process would mostly be stochastic and reversible to some extent, that is, dynamic (Figure 1 ). In this review, we show that the CSC-TPC of solid tissues share some properties with otherwise defined cancer cells: the mesenchymal types of cancer cells (epithelial mesenchymal transition cells (EMTC)) derived by epithelial-to-mesenchymal transition (EMT) from tumors and perhaps the drugtolerant persistent (DTP) cells and so on. We want to discuss the possibility that EMTC, DTP and other recently defined populations of cancer cells (for example, PKH (PKH67/PKH26, cells retaining membrane labelling dyes)-retaining cells) could be partially coexisting phenotypes.
We first summarize present concepts on CSC-TPC and EMT on recently described other populations of cancer cells and then discuss the overlap of these cell populations. The emerging field of the role of micro RNAs in the mechanisms of the CSC-TPC state and the EMT is not considered as such in this review (Shi et al., 2010) . See recent specific articles (Gunaratne, 2009; Kong et al., 2010; Mongroo and Rustgi, 2010; Castilla et al., 2011; Tellez et al., 2011) .
The cancer stem cell-tumor-propagating cell CSC-TPC are defined by their immortality, their capacity to reproduce all derived cell phenotypes of a cancer and by biological and biochemical markers (such as CD44, CD133, aldehyde dehydrogenase (ALDH), a high CD44/ CD24 ratio and so on). A detailed list of various CSC-TPC markers in different cancers can be found in Alison et al., (2010) . We first briefly summarize our previous extensive analysis of the concept (Maenhaut et al., 2010) adding a few very recent informations.
CSC-TPC biomarkers
The specificity, general applicability and congruence of expression of CSC-TPC biomarkers raise question. With regard to specificity, CD44, the major marker of breast carcinomas CSC-TPC, has been ascribed very divergent roles in different cell types. It is identified as a senescence-induced cell adhesion gene responsible for monocyte recruitment (Mun and Boo, 2010) . In lymphoma and lymphoma cell lines, it is an epigenetically suppressed inducer of apoptosis (Eberth et al., 2010) . On the other hand, CD44 expression enhances growth, self renewal and tumorosphere formation in breast carcinoma cell lines . Similarly, CD24 is considered as a negative marker of breast cancer CSC-TPC. However, in mammary development, its physiological expression correlates with the inhibition of branching morphogenesis rather than with stem progenitor cell function (Cremers et al., 2010) . In human ovarian cancer cells, CD24 expression is a positive marker of CSC-TPC (Gao et al., 2010) .
With regard to congruence of biomarkers in breast cancer cells, there was a surprisingly low overlap of cells isolated on the basis of two different biomarkers (CD44 þ /CD24 þ /À and ALDH positivity), although cells displaying both were more efficient in xenotransplants (Ginestier et al., 2007) . A similar absence of overlap between 'CSC' markers has been observed in colon cancer cells . Similarly, when three biomarkers (CD44, CD24, CD133 and so on) are used to stain human breast cancer cells as CSC-TPC, each biomarker labels a largely different cell population (Meyer et al., 2010) . However, the cells expressing the three biomarkers are the most efficient for xenotransplant or tumorosphere growth and express embryonic stem cell (ESC) biomarkers.
Some cells, exclusively generating tumor xenografts, presumably CSC-TPC, do not specifically express the classical stemness genes, for example, autofluorescent glioma cells not displaying CD133 (Clement et al., 2010) . Similarly, a 'CSC-TPC' phenotype with high aggressivity and tumorigenesis in animals, with markers of ESC (OCT4, SOX2 and NANOG) and with ALDH þ , ABCG2 þ , poly (ADP-ribose) polymerase þ and insulin-like growth factor-1 þ expressions displays the most competitive phenotype appearing in recurrent hepatocellular carcinoma but no special surface markers (Xu et al., 2010) .
Thus, CSC-TPC biomarkers are at best relatively unspecific characteristics of CSC-TPC in some cancers.
CSC-TPC quiescent or proliferative?
Originating from the well-established somatic stem cell characteristics, the CSC-TPC concept involves multiple explicit or implicit assumptions: the origin in transformed somatic stem cells and the qualitative, deterministic and irreversible character of their transformation in the derived cells, which constitute the bulk of cancers cells. Other properties have been ascribed to them, such as resistance to chemotherapy and irradiation, which could, in part, result from their assumed quiescence (Kong et al., 2010; Alison et al., 2011) . However, breast cancers treated by chemotherapy display a drop rather than an increase in CD44/CD24-high cells (Aulmann et al., 2010) .
In the definition of the CSC-TPC concept, one major question remains: are the cells the most competitive, that is, proliferative cells versus poorly competitive derived cells, as we and others argued on a dormant, slowly dividing population as previously proposed for the somatic stem cells? Most of the recent literature (Maenhaut et al., 2010) and studies (Croker et al., 2009; Clement et al., 2010; Hu et al., 2010) suggest that CSC-TPC are highly proliferative. This concept fits in well with the strong inverse correlation between the number of multiplying cancer cells and the survival of breast cancer patients, but of course other models could explain this correlation. The fraction of multiplying cells was measured by thymidine labeling (Malaise et al., 1973) or by the expression of proliferation markers (Sotiriou and Pusztai, 2009) , their number by the product of the fraction with the volume. For the rest of the review, we shall assume the concept of CSC-TPC as the most competitive cells of cancer (Maenhaut et al., 2010 (Shackleton et al., 2009; Dirks, 2010; Maenhaut et al., 2010) . As these reviews the methodological biases in the in vivo methods used to demonstrate melanoma propagating cells and the ways to possibly circumvent them have been analyzed in depth (Quintana et al., 2008; Refaeli et al., 2009) . We have proposed a dynamic view of such competitive cells based on quantitative, stochastically determined and at least partially reversible characteristics (Maenhaut et al., 2010) . The recent use of the terminology 'emergence of CSC properties' (Singh and Settleman, 2010) also implies this conclusion. The existence of a 'CSC-TPC' population in cancer cell lines cultured, that is, competing, over many generations (Ginestier et al., 2010) bears against the hypothesis of a perpetual coexistence of qualitatively, irreversibly determined populations. One possibility of maintaining over time a fractional population of CSC-TPC would be the existence of control feedback mechanisms as those operating to maintain the somatic stem cells (SSC) population (Lander, 2009) . However, this is difficult to conceive in cancer cell lines and even in cancer. Full but slow reversibility of the expression of supposed CSC markers (for example, CD44 þ /CD24
þ /À ratio) has not been properly tested. In support of a dynamic model, recent work on human breast cancer cell lines separates in a continuum the most highly ALDH-expressing cells and also cells with high CD44/ CD24 ratio. This work shows that these cells are more proliferative, adhesive and metastases generating. There is no congruence between ALDH and CD44 expressions. In this case, the CSC-TPC are the most competitive cells (Croker et al., 2009 ).
Other new arguments support a dynamic view of TPC-CSC. Their models, embryonic and somatic stem cells may themselves be in a dynamic state. Pluripotent ESC lines present a high degree of heterogeneity and interconvertibility (Pera and Tam, 2010) . Adult hair follicle somatic stem cells themselves are now considered to be constituted of two populations in equilibrium with each other: one quiescent in reserve and the other reproducing itself and generating the transit amplifying cells. Both would be long lived, give rise to each other, insuring the constancy of the population by a sophisticated retrocontrol (that is, reversible phenotypes; Li and Clevers, 2010) . Such a dynamic equilibrium between stem cells has also been demonstrated in intestinal crypts (Lopez-Garcia et al., 2010; Snippert et al., 2010 On the contrary, such a reversal was not found for highly proliferative CSC-TPC from follicular papillary and undifferentiated thyroid carcinoma cells . The 'CSC' concept implies a dichotomy between two populations of cells. In fact, cell populations in cancers are genetically very heterogeneous, as demonstrated by several groups (Campbell et al., 2010; Marusyk and Polyak, 2010; Yachida et al., 2010) . This genetic diversity within breast cancers is similar within the lesions and the invasive regions, and is predictive of progression (Merlo and Maley, 2010) .
The heterogeneity of cancer cells in space is further complicated by a possible heterogeneity in time. The permanence of CSC-TPC properties is questionable. ESCs (embryonic stem cells (ESS)) elongate their telomers once in nine passages, indicating, in this case, a sequential dynamic process (Zalzman et al., 2010) . Such a dynamic view applies even to cell lines in culture. Expression of SCA1, a CSC leukemia marker, in a cell line, is very variable from cell to cell. After cloning, the cells with the highest expression revert back to the mean level but only after 12 divisions (Chang et al., 2008) .
Such an heterogeneity in time may also apply to the required characteristics, hallmarks, of cancer cells (Hanahan and Weinberg, 2000) , which were presented as founding principles of cancers. They need not be expressed in all cancer cells or at the same time. This is synthesized in the word 'phenotypic plasticity' (Polyak and Weinberg, 2009; Marusyk and Polyak, 2010) . Besides such transient phenotypic fluctuations, cancer cell populations also evolve by genetic and epigenetic mechanisms. Evolution of these populations could be compared with the Bolero of Ravel in which at each stage new instruments, in this case new properties, enhance the sound output. Thus, the available evidence suggests that CSC-TPC are part of a dynamic continuum of differently proliferating cancer cells, expressing imperfect biomarkers, different from one cancer to another.
Epithelial-to-mesenchymal transition
Independently of the 'CSC-TPC' concept, other populations of cancer cells with special properties have been defined such as cells in EMT (Thiery, 2002; Weinberg, 2007; Nieto, 2009; Cannito et al., 2010) .
The process of EMT Tumors progress locally by collective cell migration, but some cells detach and, after an EMT (Figure 2 ), migrate Cancer cells S Floor et al separately and look like mesenchymal cells. This transition requires hours as exemplified by the fact that induction by the transcription factor SNAIL requires specific histone demethylation, that is, an epigenetic mechanism, to downregulate E cadherin . These pseudomesenchymal cells progress independently using the extracellular matrix structures as support. Such cells may become amoeboid by another transition and swim independently of the extracellular matrix structure. Hela cells in two-dimensional matrix cultures behave as mesenchymal cells, whereas in three-dimensional culture, they behave as amoeboids. The transition between these two states takes several hours and requires new transcription (C Marshall personal communication). Both types of cells move independently (Friedl and Gilmour, 2009; Yilmaz and Christofori, 2010) . In embryonic development or wounding, EMT is essentially reversible by a process called mesenchymal-to-epithelial transition (MET) (Thiery and Sleeman, 2006) .
EMT occurs at the invasive front of cancers (Wu and Zhou, 2009) . It is essential to maintain tumor-initiating capacity of transplants (Carro et al., 2010) . In pancreatic cancer, it is an independent indicator of poor prognosis (Masugi et al., 2010) . In fact, restricting the invasion phenotype of a tumor cell to a unique EMT process is a simplification. Indeed, the ability to switch between different strategies of invasion is key to cancer cell dissemination (Madsen and Sahai, 2010) . Of course, natural fibroblasts and cancer-associated fibroblasts also present characteristics of mesenchymal cells, and thus could be interpreted as cancer cells in EMT and conversely (Pietras and Ostman, 2010) .
EMT is involved in metastasis EMT endows cells with migrating and invasive properties, induces stem cell properties, prevents apoptosis and senescence, thus orchestrating the initiation of metastasis (Grunert et al., 2003; Acloque et al., 2009) . It often involves transforming growth factor (TGF)-b and SMAD (Derynck and Akhurst, 2007) . EMT cells are presumed to be responsible for metastasis (Leroy et al., 1994; Christiansen and Rajasekaran, 2006; Alexander et al., 2008; Giampieri et al., 2009; Martello et al., 2010; Pantel and Alix-Panabieres, 2010) . Here are some recent arguments for this statement.
EMT when induced by TGF-b and enhanced by the expression of ANXA1 (de Graauw et al., 2010) promotes metastasis. Solitary, presumably EMT cells (5%), of carcinoma move much more rapidly in vivo than the collective clusters, and, induced by TGF-b, intravasate into the blood vessels, whereas clusters rather invade the lymph modes (as induced by epidermal growth factor (EGF; Giampieri et al., 2009) . The motile single-cell invasions of blood vessels by rat breast carcinoma has been beautifully demonstrated (Giampieri et al., 2009; Campbell et al., 2010) . Solitary cell infiltration in pancreatic cancer is a good indication of the gravity and poor prognosis of the cancer (Masugi et al., 2010) . The genotypes of a pancreatic cancer and its various metastases show that, indeed, metastasis is clonal, with individual deposits seeded by one or a few genetically similar cells (Campbell et al., 2010) . In melanoma metastases, a reversal to original tumor phenotype(MET) has been demonstrated in vivo (Pinner et al., 2009) .
Although the role of EMT in solid tumor cell invasion in in vitro and in vivo experimental models has been beautifully illustrated, its demonstration in human tumors is more problematic. Systematic investigation in pathological materials using jointly markers of EMT and of tumor cells would be of great interest. On the other hand, tools and biomarkers that have allowed the relative purification of CSC-TPC (by cell sorting of immunolabeled or ALDH-expressing or autofluorescent cells, by tumorosphere cultures or by xenografts) have not been proposed for EMT cells.
Cells in EMT little proliferate
Although cancer cells are often considered as highly proliferative, there is less proliferation at the invasion front of carcinomas (Jung et al., 2001; Carmeliet et al., 2009) . Moreover, as cells during embryonic development, as well as tip cells during angiogenesis, stop dividing when migrating, it is likely that the cytoskeletal changes occurring during EMT are incompatible with cell division (Barrallo-Gimeno and Nieto, 2005; Richardson et al., 2006; Carmeliet et al., 2009; Giampieri et al., 2009) . In tumors, Ki67 labeling is much decreased at the invasion front (Friedl and Gilmour, 2009) . Purified invasive cells are not proliferative (Condeelis and Segall, 2003) . Moreover, a transcription factor, inducing EMT and SNAIL, induces cell cycle inhibitor p21 and represses cell cycle activator cyclin D (Vega et al., 2004) . Conversely, downregulation of cyclin A1, per se, in a breast cancer cell line increases migration and decreases proliferation (Lehn et al., 2010) . It also induces resistance to apoptosis induced by various stimuli, genotoxic stress and loss of growth factors (Kajita et al., 2004; Vega et al., 2004; Perez-Losada et al., 2005) . The latter property is shared by purified disseminating cancer cells (Goswami et al., 2004) . 
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Regulation of EMT Reversible EMT can be induced in vitro in cell culture by extracellular matrix or by extracellular signals (Coclet et al., 1991; Thiery, 2002) . In specialized differentiated cells, the dog and rat thyrocytes, it is induced by hepatocyte growth factor (HGF) and less so by EGF or even by culturing cells (Greenburg and Hay, 1988; Coclet et al., 1991) and turned of by the thyroidstimulating hormone cAMP pathway (Dremier et al., 1994) . EMT is accompanied by a switch from keratin to vimentin expression, as in model cells (Mendez et al., 2010) .
With regard to mechanisms, EMT may be induced by anoxia, which makes sense for a cancer cell, (Cannito et al., 2010) and by cancer treatment through a wound healing and cytokine response (Ouyang et al., 2010; Harless, 2011) . It can be caused not only by each of several extracellular signals, such as TGF-b, interleukin-6, tumor necrosis factor-a, EGF, HGF, fibroblast growth factor, NOTCH, insulin-like growth factor-1, CXCL12, but also by metalloproteases, such as MMP3, secreted by cells in the environment, for example, cancer-associated fibroblasts and inflammatory cells such as macrophages (Reiman et al., 2010) . These act through the induction of transcription factors (SLUG, SNAIL, twist, goosecoid, ZEB1 or ZEB2 and so on), which act as molecular switches by repressing genes of cell-cell and cell-matrix interactions, such as cadherins, claudins, occludins, desmoplakin 201, integrins, takophilin, keratin 8, 18, 19 and mucins, and inducing other genes, such as vimentin and N cadherin (Berx and van Roy, 2009; Tomaskovic-Crook et al., 2009; Wu and Zhou, 2009; Ohashi et al., 2010; Singh and Settleman, 2010) . Vimentin has been shown to be both a marker and an essential causal element of the EMT (Mendez et al., 2010) . Transcriptional effects may be reinforced by epigenetic mechanisms . Matrix metalloprotease expression by itself cleaves E cadherin in mammary epithelial cells and induces an EMT (Lochter et al., 1997) .
TGF-b signaling often has a crucial role in EMT. It is involved in the maintenance of leukemia-initiating cells in vivo and in the development of colonies in vitro (Naka et al., 2010) . A TGF-b inhibitor inhibits tumorosphere formation by murine breast cancers and also tumor growth and metastasis (Bandyopadhyay et al., 2010) . The EMT-inducing effect of TGF-b is mediated in transformed hepatocytes by the induction of growth factors in stromal myofibroblasts, which themselves cause EMT (van Zijl et al., 2009 ). In the RAS-RAF pathway, extracellular signal-regulated kinase 2 (ERK2) would specifically be involved in EMT induction but not ERK1 (Shin et al., 2010) . cJun may be an intermediate. When overexpressed in response to ERBB2 in mammary gland, it induces both invasion and mammosphere growth (Jiao et al., 2010) .
Conversely to EMT, suppression of autocrine motility factor in various cancer cell lines induces MET (Niinaka et al., 2010) . Expression of GATA3 in a breast cancer cell also reverses EMT, that is, induces MET (Yan et al., 2010) . , dormancy and so on) and that these are reversible. The overlap of CSC-TPC and EMT properties has already been discussed (Alexander et al., 2008; TomaskovicCrook et al., 2009; Singh and Settleman, 2010) . We review here new recent examples of common expressions of CSC-TPC, EMT, invasive and chemoresistance characteristics.
Cells isolated from breast carcinomas using protocols known to enrich 'breast CSCs', more malignant than non-CSC-TPC, show clear evidence of EMT (Thiery, 2002) . There is a concomitant acquisition of malignant and some stem cell traits in EMT (Polyak and Weinberg, 2009 ). Both EMT and CSC-TPC properties are induced by hypoxia in human mammary cancer cell lines (Louie et al., 2010) .
CD44, the main biomarker of breast cancer 'CSC', promotes invasive growth (Pusch et al., 2010) . It is part of the MET-HGF complex involved in the migration of many cancer cells (Yilmaz and Christofori, 2010) . High levels of the supposed CSC marker CD133 in colon cancers is predictive of metastasis , that is, possibly of its first step in EMT. Cells from human prostate cell lines, selected for high expression of the 'CSC' marker ALDH, display stronger migratory behavior in vitro and 'metastatic' generation in vivo than (Morel et al., 2008) and TGF-b actors. Cancerassociated fibroblasts, through metalloproteases, induce EMT in prostate cancer cells and cell lines, and enhance the expression of stem cell markers and the ability to form tumorospheres (Giannoni et al., 2010) . As expected from CSC-TPC, an EMT phenotype is associated with therapeutic resistance and invasive metastasis (Xie et al., 2010) in prostate cancer.
The relation between EMT and CSC-TPC properties has been developed by Weinberg's group (Weinberg, 2007) with induction of EMT by transcription factors TWIST and SNAIL, which also endow breast-immortalized epithelial cells with stem cell-like properties, such as the ability to form mammospheres in three-dimensional cultures (Mani et al., 2008) . Conversely, EMT characteristics are demonstrated in normal and neoplastic stem cells isolated from in vivo tissue. The review of Singh and Settleman (2010) even implies that the EMT program induces the CSC-TPC program. Of course, cells poised for extravasation and metastasis would be expected to grow in suspension or xenotransplants.
EMT cells, as CSC-TPC, are more resistant to therapy, for example, circulating tumor cells positive for EMT markers and stem cells markers (ALDH1) (Aktas et al., 2009) ; transformed EMT breast cancer cells are more resistant to chemotherapy (Gupta et al., 2009 ) and cell lines to apoptosis (Robson et al., 2006) .
The EMT transcription factors, SNAIL and SLUG, mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and by conferring a stem-like phenotype in ovarian cancer cells (Kurrey et al., 2009) . Classical growth control pathways, particularly TGF-b but also EGF, are involved in the generation of both 'CSC' and EMT phenotypes. TGF-b is overexpressed at the invasive front of papillary thyroid carcinomas (PTCs) (Riesco-Eizaguirre et al., 2009). The inverse relation among SMAD3 levels, the intracellular transducer of TGF-b, and proliferation suggests a temporal either/or choice between proliferation and TGF-b action, including its effect on EMT (Daly et al., 2010) .
EGF activates ERK, which induces SLUG and therefore causes migration (Chen et al., 2009) . EGF through ERK2, but not ERK1, induces FRA1, which induces both EMT transcription factors (SNAIL, SWG, TWIST and ZEB) and the CSC-TPC marker CD44, and represses the negative CSC marker CD24 in the non-transformed human breast cell line MCF 10A (Shin et al., 2010) . A reversible switch in metastasis between EMT and stemness properties on the one hand and MET and differentiation on the other hand could be controlled by a positive feedback loop involving ZEB1 and micro RNA-200 family (Brabletz and Brabletz, 2010) .
cJun induces jointly cellular invasion in vivo and in vitro and breast CSC-TPC characteristics (as evidenced by tumorosphere growth, CD44/CD24 biomarker ratio, expression of ALDH and Sca1) in ERBB2-expressing transgenic mice mammary cancer cells. Although the first effect was mediated by CCL5, the second was secondary to SCF induction (Jiao et al., 2010) .
In conclusion, programs of EMT cells and CSC-TPC overlap. Of course, correlation of expression does not necessarily imply direct causal relations, for example, a common Myc-induced network accounts for similarities between embryonic stem and cancer cell transcription programs (Kim et al., 2010) .
The relation of CSC-TPC and EMT properties with cell proliferation is not obvious. Indeed, classically EMT cells do not proliferate. If TPC-CSC are the dormant cells that proliferate slowly and thus escape chemotherapy (Sell, 2006) , this is compatible with cells in EMT and is in keeping with the conventional description of CSC-TPC. If on the other hand, they are the most competitive highly reproducing cells (Yeung et al., 2010) , this definition is at first sight incompatible with EMT. The problem of this type of reasoning is that it assumes that such populations of cells are fixed. An overlap of CSC-TPC and EMT properties with proliferation may not be simultaneous. If, as generally assumed, the EMT state represents a transient phase in the lifetime of the cells, it is conceivable that the most competitive TPC when separated from other cells adopt transiently an EMT state that allows them to invade, metastasize and then reconvert to their previous highly proliferating state in the new site. In this case, some biomarkers of CSC-TPC or EMT would only be expressed at some stages of this process.
In an oligodendrioma cell line, the expression of the supposed CSC-TPC marker CD133 is inversely correlated to telomerase expression (Shervington et al., 2009 ). This counterintuitive finding could be explained by a temporal reversible dissociation of the two expressions. This problem could perhaps be clarified by testing the coexpression of markers of CSC-TPC and markers of proliferation (for example, KI67, PCNA, thymidine labeling, etc) or its absence. One unifying concept is that cancer cells may exhibit different but partially overlapping programs (for example, TPC, EMT, drug tolerant persisters (DTP) and so on) more or less at different times, that is, with different rates of reversibility (Roesch et al., 2010) . EMT, as the intermediate stage between the solid tumor and invasion and metastasis , is a reversible and transient process. This is clearly different from the Cancer cells S Floor et al CSC-TPC state, which is, at best, a relatively stable and slowly reversible state. The resistance to chemotherapy and X-rays of CSC-TPC could be due to properties, such as enhanced DNA repair, impaired apoptosis, as well as the transient quiescent EMT state.
Independently of the program they express, the fate of the cancer cells also depends on their localization. Cancers in tissues shedding regularly their cells outside, that is, lumen-bordering epithelia such as digestive or airways mucosae or the skin, are interesting with regard to the role of the environment in determining the fate of the cancer cells: CSC-TPC or derived cells. Obviously, the cells growing toward the outside would be confined in the bulk of the tumor. EMT cells, if they appear, would be shed and doomed. On the other hand, the cells crossing the basal membrane and invading the conjunctive tissue would be TPCs and would have to undergo EMT to metastasize.
Other described sub-populations of cancer cells and CSC-TPC
Other properties than EMT may account for the 'CSC-TPC' drug resistance.
Heterogeneity often allows organisms to adapt to changing environmental conditions, constituting the basis of Darwinian selection. In bacteria, for instance, up to 1% of a previously non-exposed population may show drug resistance caused by non-genetic mechanisms such as reduced proliferation (that is, a dormant, nondividing state; bet hedging). A similar, epigenetically driven, phenomenon was observed in a PL9 lung cancer cell line, that is, a cloned population (Sharma et al., 2010) . In these cells, DTP, tolerant to drugs, develop spontaneously from single-drug sensitive clones. Most do not proliferate and they express CSC markers (CD133 and CD24) but some (20%) evolve and proliferate, losing CSC markers (drug-tolerant expanded persisters). Interestingly, when no longer submitted to drugs, drug-tolerant expanded persisters slowly reverted to the initial parent phenotype. The phenotype is very slowly reversible when no longer selected (after passage 30; Sharma et al., 2010) .
The characteristics of these DTP cells are suppressed by histone deacetylase inhibitors and require an K4 histone demethylase (KDM5A/JARID1A). Histone deacetylase inhibition phenocopies KDM5A knockdown, leading to rapid death of DTP and drug-tolerant expanded persistent cells in response to chemotherapy. This suggests that these cells are epigenetically determined (Sharma et al., 2010) . Moreover, the frequency of their emergence is much higher than would be expected from mutational mechanisms. The analogy of DTP characteristics with some properties of CSC-TPC was noticed. Thus, whole DTP could be isolated by CSC-TPC-purifying methods based on biomarker expression, and thus 'contaminate' this population. drug-tolerant expanded persisters that have lost these markers would not.
Low-division (that is, PKH retaining) cells in cell lines originating from mice tumors are not in cell cycle (Ki67 low). They highly express CD44, CK19, NA-NOG, Nestin and OCT4, that is, putative CSC-TPC markers. The proportion of these cells in the population increased after chemotherapy. These properties would qualify them as CSC-TPC. Among the quiescent PKHexpressing cells, there was also an aneuploid population with low proliferation, from which drug-resistant proliferative clones might arise. No such cells were observed in cell culture conditions. This suggests that this population results from intrinsic and extrinsic elements in tumor formation, controlling a switch between different states, which itself may indicate a reversibility of quiescence (Kusumbe and Bapat, 2009 ).
Discussion
The possibility that the so-called TPC-CSC could be contaminated by, or could be, cancer cells in mesenchymal transition, drug-resistant cells or other types of cancer cells raises several questions.
First, the definition of TPC-CSC themselves: a minimal definition such as proposed by Dalerba (cancer cells with infinite lifespan able to generate all types of differentiated derived cells found in a cancer) has the advantage that it corresponds to a strict basic operational definition. However, it opens the possibility that the definition could include different types or cells.
Immunological or biological biomarkers are often used to characterize and purify the TPC-CSC. However, the fact that these defining biomarkers only partially overlap between different cancer types suggests, at least, that these characteristics do not belong to the core properties attributed to such cells. We have even seen (see 'CSC-TPC biomarkers') that some markers, as CD24, have opposite roles in different cancer cells (Gao et al., 2010) . The use of one criterion to define the TPC will, therefore, also favor the inclusion of different cell populations in this category. In this article, we suggest that, as defined, the TPCs could include or be contaminated by other types of cells such as the cancer cells in EMT. Certainly, EMT cells that presumably invade and metastasize in vivo should be successful in xenograft assays and for growth in the absence of solid substrate, that is, in the functional assays used for CSC-TPC. As they are not yet well characterized in in vivo cancers, we shall not further discuss DTPs and slowly dividing cells (PKH), which could also overlap with CSC-TPC population.
Second, the concept of TPC-CSC as qualitatively different, distinct, permanent population of cells. This is not necessarily implicit in Dalerba definition. In fact there are many arguments in favor of a more dynamic view. As already discussed, the concept of separate noninterchangeable populations of CSC-TPC growing side by side over many generations is almost impossible to conceive in cancer cell lines from which CSC-TPC have been derived. The induction by DNA damage inducers (ultraviolet and mitomycin), within a short (2 days) time, of an increased of proportion of such cells, in two human cancer cell lines (nasopharyngeal carcinoma and neuroblastoma) certainly suggests a transition of derived cells to a CSC-TPC phenotype (Liang et al., 2010) . In a glioma cell line, there is an inverse relation between the expression of the 'CSC' marker CD133 and the expression of telomerase. Serum represses the former and induces the latter. Thus, among these cells, the 'CSC-TPC' would be the least equipped for long survival. These findings clearly suggest a dynamic equilibrium between the two forms (Shervington et al., 2009; Maenhaut et al., 2010; Roesch et al., 2010) .
As expected from the reversibility concept, in human cervical cancer cell lines, cells with a CSC-TPC-like phenotype, after growth as non-adherent cells in vitro, (stem cell markers, ALDH activity, verapamil resistance) completely revert their phenotype after growth in adherent conditions (Bortolomai et al., 2010) . Even the supposedly irreversible senescence allows after long delays the emergence of clones with genetic aberration and sustained proliferation (Gosselin et al., 2009) . Reversibility of the DTP phenotype has also been demonstrated (Sharma et al., 2010) . The EMT phenotype itself is certainly reversible as, after metastasis, the cells reproduce the phenotypes of the originating bulk tumor (Sharma et al., 2010) . We presume that the hypothesis of dynamics also applies to the so-called hallmarks of cancer (Hanahan and Weinberg, 2000) . TPC and EMT properties as well as hallmarks are properties of cancer cells, but they need not be expressed in all cancer cells, nor at all times in a given cell.
Within the framework of a dynamic concept of TPC, it is conceivable that cancer cells may display concomitantly or consecutively different partially overlapping or even exclusive of each other's programs (TPC, EMT, DTP and PKH) with more or less rapid transitions. Epigenetic changes characteristic of stem or progenitor cells may be among the earliest events in cancer initiation (Feinberg et al., 2006; Sharma et al., 2010) , suggesting a reappropriation of such a program. The time scale of such transitions may vary much for different programs. Different thyroid cells in vitro begin to respond to an acute thyroid-stimulating hormone stimulus with a delay of 5 min to 3 h for secretion, of 18 h to 3 days for DNA synthesis (Neve and Dumont, 1970; Baptist et al., 1993) . Single expression of mRNA in individual cells in a population occurs in bursts, which may be synchronized or not (Janes et al., 2010; Stahlberg and Bengtsson, 2010) . Cells in culture take 12 h to shift from the mesenchymal to ameboid types. The fact that the EMT-inducing transcription factor SNAIL uses an histone-specific demethylation to cause one of its major effects, the downregulation of E cadherin, implies relatively long time-scale effects . The maintenance of telomeres in ESCs required telomerase expression only once in nine passages (Zalzman et al., 2010) . We have seen that DTP phenotypes switch back to normal after 30 generations. The dynamic view of cancer cell populations also fits well with the growing concept of the role of microenvironment in cancer. Not only does the microenvironment participate in the genesis and progression of tumors but also it can be presumed that different microenvironments in one tumor may induce or select different phenotypes. In shedding epithelia, the CSC-TPC and derived cells are pushed in the lumen, fitting the derived cells definition, whereas the same cells breaking the basal membrane and undergoing EMT would fit the CSC-TPC definition.
On a more practical level, this analysis suggests the interest of testing isolated CSC-TPC for the presence of other described cancer cell phenotypes among them. The CSC-PTC and the EMT concepts have both been mostly developed using experimental models. Both may concern relatively small populations. Whether these two populations overlap, in vivo, is an open question. This could be investigated by the consecutive application of separation methods based on biomarkers, respectively, of TPC-CSC and EMT cells in a given cancer type. This may be difficult because of the low proportion of such cells in a cancer. On the other hand, the joint use of several biomarkers on histological preparations could indicate in vivo colocalization or its absence (see, for example, CSC-TPC markers (Meyer et al., 2010; Roesch et al., 2010) . As EMT is a reversible process, EMT cells included in the CSC-TPC populations would thus constitute within this population a reversible phenotype. This and the in vivo localization of such cells in tumor would require a systematic study of the expression of several markers of each population in individual tumors.
One unifying concept is that cancer cells may exhibit different but partially overlapping programs (for example, TPC, EMT, DT and so on) (Davidson, 2010) more or less at different times, that is, with different rates of reversibility. As in the case of invasion, tumor cells must resort at different times to different strategies, that is, programs, to progress (Madsen and Sahai, 2010) . This implies a reversibility between these programs, as recently analyzed (Mills, 2010; Chang et al., 2011) . One example is the activated CD8T cells that stimulate mammary epithelial tumor cells to undergo EMT and acquire the increased tumorigenic capability and chemotherapeutic resistance of breast CSCs. This is reversible. However, the characterization of such cells as CSC-TPC is extrapolated (Reiman et al., 2010) .
Some EMT cells, if they are the vectors of metastasis, should be CSC-TPC to generate the full cell diversity of metastasis. On the other hand, CSC-TPC, to metastasize, should undergo EMT and then MET . Thus, the two cell programs CSC-TPC and EMT should overlap at least at some time. Tumor cells that succeed to generate metastasis would therefore be those CSC-TPC that have undergone EMT and escaped from the tumor (so-called 'migrating stem cells' (Wellner et al., 2009;  Figure 3 ). This would contribute to explain the very small proportions of the great number of circulating tumor cells produced continuously that succeed to generate metastases (metastatic inefficiency). Metastasizing non-TPCs would at worst only produce dormant metastases. The propagation, not the seeding, is the limiting step (Podsypanina et al., 2008) . Similar transitions may occur several times. Indeed, DNA sequencing of a pancreatic cancer and its metastases suggests the existence of secondary and tertiary metastases (Campbell et al., 2010) . Thus, our tentative conclusion would be that TPC and EMT programs overlap in some cells at some time. They may even favor each other but, at any given time, only a minor fraction of CSC-TPC would be in EMT.
Presumably, EMT cells in solid tumors would be located at the interfaces of the tumor with the environment (invaded tissue at invasive front, vessels and so on; Nieto, 2009; Thiery et al., 2009; Wu and Zhou, 2009 ) except, perhaps, in very fibrotic lesions. This implies that they would represent only a minor fraction of the tumor cells (population size proportional to the surface and not volume of the tumor), whereas the number of CSC-TPC would be expected to be proportional to the volume of the tissue.
Certainly, in progressing papillary thyroid carcinomas, TGF-b, the inducer of EMT is overexpressed at the invasive front, whereas a differentiation marker is preferentially expressed inside the tumor (Riesco-Eizaguirre et al., 2009). In squamous cell carcinoma and bladder cancers, putative CSC-TPC are located at the tumor-stroma interface (Atsumi et al., 2008; He et al., 2009) , in brain and liver close to capillaries (Calabrese et al., 2007; Lingala et al., 2010) , but in many tumors, the markers are dispersed. (Aulmann et al., 2010; Todaro et al., 2010) .
There is another reason why the fraction of CSC-TPC that are also EMT cells is probably minor. Whereas the CSC-TPC state is apt to be quasi irreversible for those characteristics that are genetic, partly slowly reversible for those that result from epigenetic factors, that is, of long duration, the EMT state resulting from transcriptional and epigenetic effects is apt to be more transient. The EMT state being more transient would be less frequent.
Conclusions
The phenotype of any cell, for example, CSC-TPC or EMT, energy metabolism configuration and so on, reflects the programs that shape it: cell ultrastructure, apoptosis, autophagy, proliferation, differentiation, loss of tissue structure, escape from local control, angiogenesis, fibrosis, inflammation and so on. Such programs might be genetic and quasi irreversible unless corrected downstream, epigenetic or lysogenic and slowly or occasionally reversible, translational or resulting from enzymatic activity and rapidly reversible. They might be intrinsic (for example, genetic) or result from cross signaling with the microenvironment. They might be exclusive of each other (for example, EMT versus MET, senescence versus proliferation and differentiation versus stemness of SSC), more or less overlapping (as in the case of CSC-TPC and EMT programs) or even linked. Of course, the relative expression of these programs will depend on the nature of the cell of origin, the oncogenic stimuli and the environment.
Cancers could be conceived as populations of competing cells, each with its own programs, as shaped by its history and environment, submitted to both a continuous adaptation and a Darwinian evolution. In fact, such a competition between stem cells accounts for intestinal crypt homeostasis (Snippert et al., 2010) . Of course, pictures we get of in vivo tumors at a given time would give the wrong impression of stability to what is in fact a very dynamic state.
Collectively, these competing cells, each regulated by its simple programs, would display, as insect populations, a sort of collective intelligence, leading to the expansion of the tumor at the expense of the host. The endothelial differentiation of glioblastoma cells could be a good example of such adaptations (RicciVitiani et al., 2010) . We guess that this behavioral independence would be acquired progressively with the programs during the development of the tumor.
These concepts further suggest the interest of a multipronged therapy attacking various cancer programs simultaneously or consecutively (Singh and Settleman, 2010 Figure 3 Tumor invasion and metastasis with EMT of peripheral cells involving both CSC-TPC and derived cells. The reverse transition (MET) takes place after seeding, but only the CSC-TPC proliferate and generate a metastasis. The scheme does not exclude the possibility that tumors in bulk may invade the vessels but only those emerging EMT would be carried out by the blood flow.
Cancer cells S Floor et al

